---
title: "Profound Medical Corp. (PROF.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PROF.US.md"
symbol: "PROF.US"
name: "Profound Medical Corp."
industry: "Health Care Equipment"
datetime: "2026-04-16T18:44:55.317Z"
locales:
  - [en](https://longbridge.com/en/quote/PROF.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PROF.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PROF.US.md)
---

# Profound Medical Corp. (PROF.US)

## Company Overview

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [www.profoundmedical.com](https://www.profoundmedical.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-16T04:30:16.000Z

**Overall: C (0.43)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 75 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 50.73% |  |
| Net Profit YoY | -53.04% |  |
| P/B Ratio | 3.51 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 233000880.24 |  |
| Revenue | 16098000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -67.12% | E |
| Profit Margin | -264.44% | E |
| Gross Margin | 70.77% | A |
| Revenue YoY | 50.73% | A |
| Net Profit YoY | -53.04% | D |
| Total Assets YoY | 10.31% | B |
| Net Assets YoY | 9.95% | B |
| Cash Flow Margin | 89.75% | C |
| OCF YoY | 50.73% | A |
| Turnover | 0.22 | D |
| Gearing Ratio | 14.25% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Profound Medical Corp.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "50.73%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-53.04%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.51",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "233000880.24",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "16098000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-67.12%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-264.44%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "70.77%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "50.73%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-53.04%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "10.31%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "9.95%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "89.75%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "50.73%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.22",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "14.25%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.47 | 125/183 | - | - | - |
| PB | 3.51 | 84/183 | 7.19 | 3.64 | 3.15 |
| PS (TTM) | 14.47 | 124/183 | 17.08 | 14.43 | 12.84 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Abbott Laboratories (ABT.US) | B | C | C | C | B | B |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | B | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | B | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-20T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 80% |
| Overweight | 1 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 6.41 |
| Highest Target | 13.00 |
| Lowest Target | 11.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PROF.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PROF.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PROF.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PROF.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**